This text discusses various studies related to adjuvant chemotherapy for non-metastatic colon cancer, including the impact of KRAS mutations on disease-free survival, the duration of oxaliplatin-based chemotherapy, and the use of a 12-gene recurrence score to predict recurrence in patients with stage II and III colon cancer.